419 related articles for article (PubMed ID: 21850690)
21. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS
Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
[TBL] [Abstract][Full Text] [Related]
22. A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial.
Baran DA; Zucker MJ; Arroyo LH; Camacho M; Goldschmidt ME; Nicholls SJ; Prevost-Fernandez J; Carr C; Adams L; Pardi S; Hou V; Binetti M; McCahill J; Chichetti J; Viloria V; Sanagustin MG; Ebuenga-Smith J; Mele L; Martin A; Blicharz D; Wolski K; Olesnicky L; Qian F; Gass AL; Cohen M
Circ Heart Fail; 2011 Mar; 4(2):129-37. PubMed ID: 21216835
[TBL] [Abstract][Full Text] [Related]
23. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes.
Humar A; Crotteau S; Gruessner A; Kandaswamy R; Gruessner R; Payne W; Lake J
Clin Transplant; 2007; 21(4):526-31. PubMed ID: 17645714
[TBL] [Abstract][Full Text] [Related]
24. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
25. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
Guethoff S; Meiser BM; Groetzner J; Eifert S; Grinninger C; Ueberfuhr P; Reichart B; Hagl C; Kaczmarek I
Transplantation; 2013 Feb; 95(4):629-34. PubMed ID: 23423270
[TBL] [Abstract][Full Text] [Related]
26. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
Abramowicz D; Vanrenterghem Y; Squifflet JP; Kuypers D; Mourad M; Meurisse M; Wissing M
Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591
[TBL] [Abstract][Full Text] [Related]
28. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
29. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation.
Reggiani P; Arru M; Regazzi M; Gatti S; Molinaro MD; Caccamo L; Maggi U; Melada E; Paone G; Rossi G
Transplant Proc; 2005 May; 37(4):1697-9. PubMed ID: 15919435
[TBL] [Abstract][Full Text] [Related]
30. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
[TBL] [Abstract][Full Text] [Related]
31. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
Boillot O; Mayer DA; Boudjema K; Salizzoni M; Gridelli B; Filipponi F; Trunecka P; Krawczyk M; Clavien PA; Ducerf C; Margarit C; Margreiter R; Pallardo JM; Hoeckerstedt K; Pageaux GP
Liver Transpl; 2005 Jan; 11(1):61-7. PubMed ID: 15690537
[TBL] [Abstract][Full Text] [Related]
32. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Zimmerman MA; Trotter JF; Wachs M; Bak T; Campsen J; Skibba A; Kam I
Liver Transpl; 2008 May; 14(5):633-8. PubMed ID: 18324656
[TBL] [Abstract][Full Text] [Related]
33. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.
Wiesner RH; Shorr JS; Steffen BJ; Chu AH; Gordon RD; Lake JR
Liver Transpl; 2005 Jul; 11(7):750-759. PubMed ID: 15973716
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
Ekberg H; Bernasconi C; Tedesco-Silva H; Vítko S; Hugo C; Demirbas A; Acevedo RR; Grinyó J; Frei U; Vanrenterghem Y; Daloze P; Halloran P
Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339
[TBL] [Abstract][Full Text] [Related]
35. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
Manousou P; Samonakis D; Cholongitas E; Patch D; O'Beirne J; Dhillon AP; Rolles K; McCormick A; Hayes P; Burroughs AK
Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
[TBL] [Abstract][Full Text] [Related]
36. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
[TBL] [Abstract][Full Text] [Related]
37. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.
Chan K; Taube D; Roufosse C; Cook T; Brookes P; Goodall D; Galliford J; Cairns T; Dorling A; Duncan N; Hakim N; Palmer A; Papalois V; Warrens AN; Willicombe M; McLean AG
Transplantation; 2011 Oct; 92(7):774-80. PubMed ID: 21836540
[TBL] [Abstract][Full Text] [Related]
38. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
Orr DW; Portmann BC; Knisely AS; Stoll S; Rela M; Muiesan P; Bowles MJ; Heaton ND; O'Grady JG; Heneghan MA
Transplant Proc; 2005 Dec; 37(10):4373-9. PubMed ID: 16387124
[TBL] [Abstract][Full Text] [Related]
39. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
40. Impact of steroid-avoidance immunosuppression on long-term outcome after liver transplantation for HCV cirrhosis: the need for well documented long-term follow-up.
Bonaccorsi-Riani E; Sempoux C; Piette N; Julliard O; Kabamba B; Ciccarelli O; Roggen F; De Reyck C; Hassoun Z; Lerut J
Acta Gastroenterol Belg; 2012 Dec; 75(4):411-8. PubMed ID: 23402084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
